Completed PHASE1 INTERVENTIONAL NCT00000762

A Placebo-Controlled, Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant Envelope Proteins of HIV-1 gp160 and gp120 in Children >= 1 Month Old With Asymptomatic HIV Infection

Sponsor: Genentech, Inc.

Interventions gp160 Vaccine (MicroGeneSys) rgp120/HIV-1 SF-2 rgp120/HIV-1MN

Updated 6 times since 2017 Last updated: Oct 27, 2021 Completion: Feb 29, 1996

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates HIV Infections and is currently completed. Genentech, Inc. leads this study, which shows 6 recorded versions since 2026 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Dec 2021 — Jul 2024 [monthly]

Completed PHASE1
Jan 2021 — Dec 2021 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Genentech, Inc.
MicroGeneSys Inc (nka Protein Sciences Corporation)
National Institute of Allergy and Infectious Diseases (NIAID)

Data source: National Institute of Allergy and Infectious Diseases (NIAID)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Baltimore, United States , Boston, United States , Brooklyn, United States , Chicago, United States , Durham, United States , Farmington, United States , Great Neck, United States , Houston, United States , Long Beach, United States , Los Angeles, United States and 15 more locations